| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NIVFWNewGenIvf Group Limited | 19.81K | 0.02 | -0.00 | 5.78% | -16.52% | -59.53% | ||
| NIVFNewGenIvf Group Limited | 677.01K | 0.51 | -0.02 | 5.78% | -16.52% | -59.53% |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Sales/Revenue | 4.12M | 5.94M | 5.14M | 5.43M |
| Revenue Growth % | - | 0.44% | -0.14% | 0.06% |
| Cost of Goods Sold | 3.09M | 4.41M | 3.45M | 3.61M |
| COGS % of Revenue | 0.75% | 0.74% | 0.67% | 0.66% |
| Gross Profit | 1.02M | 1.54M | 1.68M | 1.83M |
| Gross Margin % | 0.25% | 0.26% | 0.33% | 0.34% |
| Gross Profit Growth % | - | 0.5% | 0.09% | 0.09% |
| Operating Expenses | 826.02K | 1.14M | 1.64M | 2.8M |
| OpEx % of Revenue | 0.2% | 0.19% | 0.32% | 0.52% |
| Selling, General & Admin | 826.02K | 1.14M | 1.64M | 2.99M |
| SG&A % of Revenue | 0.2% | 0.19% | 0.32% | 0.55% |
| Research & Development | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 64 | 0 | -186.39K |
| Operating Income | 198.76K | -504.91K | 42.24K | -1.16M |
| Operating Margin % | 0.05% | -0.08% | 0.01% | -0.21% |
| Operating Income Growth % | - | -3.54% | 1.08% | -28.46% |
| EBITDA | 541.3K | -200.96K | 271.95K | -953.74K |
| EBITDA Margin % | 0.13% | -0.03% | 0.05% | -0.18% |
| EBITDA Growth % | - | -1.37% | 2.35% | -4.51% |
| D&A (Non-Cash Add-back) | 342.54K | 303.94K | 229.71K | 206.26K |
| EBIT | 244.47K | 421.75K | 154.6K | -182K |
| Net Interest Income | -88.23K | -77.74K | -45.66K | -772K |
| Interest Income | 63 | 21 | 518 | 6.95K |
| Interest Expense | 88.29K | 77.76K | 46.18K | 778.66K |
| Other Income/Expense | -42.57K | 1.01M | 66.18K | 199.69K |
| Pretax Income | 156.18K | 500.65K | 108.42K | -961K |
| Pretax Margin % | 0.04% | 0.08% | 0.02% | -0.18% |
| Income Tax | 294.72K | 208.14K | 0 | -487K |
| Effective Tax Rate % | -0% | 0.92% | 1.2% | 0.55% |
| Net Income | -533 | 458.67K | 130.19K | -525K |
| Net Margin % | -0% | 0.08% | 0.03% | -0.1% |
| Net Income Growth % | - | 861.54% | -0.72% | -5.03% |
| Net Income (Continuing) | -138.53K | 135.85K | 108.42K | -474K |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | -138.97K | -462.43K | -490.05K | -433.14K |
| EPS (Diluted) | -0.01 | 64.60 | 12.85 | -23.05 |
| EPS Growth % | - | - | -0.8% | -2.79% |
| EPS (Basic) | -0.01 | 64.60 | 12.85 | -23.05 |
| Diluted Shares Outstanding | 50.74M | 193.69K | 253.73K | 569.25K |
| Basic Shares Outstanding | 50.74M | 193.69K | 253.73K | 569.25K |
| Dividend Payout Ratio | - | - | - | - |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Total Current Assets | 820.39K | 91.73K | 2.46M | 3.17M |
| Cash & Short-Term Investments | 28.76K | 54.72K | 54.1K | 457.74K |
| Cash Only | 28.76K | 54.72K | 54.1K | 457.74K |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 750.35K | 2.32M | 519.55K | 2.36M |
| Days Sales Outstanding | 66.51 | 142.72 | 36.92 | 158.72 |
| Inventory | 41.27K | 46.91K | 126.26K | 80.81K |
| Days Inventory Outstanding | 4.87 | 3.89 | 13.34 | 8.18 |
| Other Current Assets | 0 | -2.33M | 373.68K | 73.92K |
| Total Non-Current Assets | 592.38K | 70.69M | 2.03M | 609K |
| Property, Plant & Equipment | 592.38K | 506.34K | 446K | 371.67K |
| Fixed Asset Turnover | 6.95x | 11.74x | 11.52x | 14.62x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 70.69M | 21.26M | 204K |
| Other Non-Current Assets | 0 | -506.34K | -19.67M | 33.33K |
| Total Assets | 1.41M | 70.79M | 4.49M | 3.58M |
| Asset Turnover | 2.91x | 0.08x | 1.14x | 1.52x |
| Asset Growth % | - | 49.1% | -0.94% | -0.2% |
| Total Current Liabilities | 2.07M | 50K | 1.12M | 2.72M |
| Accounts Payable | 46.93K | 104.65K | 172.63K | 1.3M |
| Days Payables Outstanding | 5.54 | 8.67 | 18.24 | 131.48 |
| Short-Term Debt | 512.82K | 0 | 213.57K | 582.45K |
| Deferred Revenue (Current) | 812.16K | 1000K | 7.94K | 63.49K |
| Other Current Liabilities | 0 | -2.51M | -15.59K | 554.38K |
| Current Ratio | 0.40x | 1.83x | 2.19x | 1.17x |
| Quick Ratio | 0.38x | 0.90x | 2.08x | 1.14x |
| Cash Conversion Cycle | 65.84 | 137.93 | 32.02 | 35.42 |
| Total Non-Current Liabilities | 261.82K | 2.42M | 118.98K | 2.34M |
| Long-Term Debt | 0 | 0 | 0 | 2.33M |
| Capital Lease Obligations | 261.82K | 248.63K | 118.98K | 10.23K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 2.17M | 0 | 0 |
| Total Liabilities | 2.33M | 2.46M | 1.24M | 5.06M |
| Total Debt | 925.97K | 452.04K | 332.55K | 3.03M |
| Net Debt | 897.2K | 397.32K | 278.45K | 2.57M |
| Debt / Equity | - | 0.01x | 0.10x | - |
| Debt / EBITDA | 1.71x | - | 1.22x | - |
| Net Debt / EBITDA | 1.66x | - | 1.02x | - |
| Interest Coverage | 2.25x | -6.49x | 0.91x | -1.49x |
| Total Equity | -914.91K | 67.86M | 3.25M | -1.48M |
| Equity Growth % | - | 75.17% | -0.95% | -1.46% |
| Book Value per Share | -0.02 | 350.35 | 12.79 | -2.60 |
| Total Shareholders' Equity | -775.94K | 68.32M | 3.74M | -1.05M |
| Common Stock | 5.6K | 67.34M | 21.27M | 0 |
| Retained Earnings | -1.05M | -591.54K | -461.35K | -985.99K |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 10.85K | 9.57K | -7.29K | 18.88K |
| Minority Interest | -138.97K | -462.43K | -490.05K | -433.14K |
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Cash from Operations | 1.43M | -527.12K | -1.79M | -8.26M |
| Operating CF Margin % | 0.35% | -0.09% | -0.35% | -1.52% |
| Operating CF Growth % | - | -1.37% | -2.4% | -3.61% |
| Net Income | -138.53K | 500.65K | 130.19K | -474.1K |
| Depreciation & Amortization | 342.54K | 303.94K | 229.71K | 206.26K |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 208.14K | 0 | -486.71K |
| Other Non-Cash Items | 497.6K | -2.25M | -60.51K | 247.54K |
| Working Capital Changes | 731.39K | 710.35K | -2.09M | -7.76M |
| Change in Receivables | 56.18K | 129.92K | 1.17K | -39.87K |
| Change in Inventory | 1.35K | -7.22K | -80.67K | 45.45K |
| Change in Payables | -60.99K | 58.75K | 567.4K | 1.13M |
| Cash from Investing | -16.57K | -69.69M | -69.85K | -53.05K |
| Capital Expenditures | -16.57K | -94.45K | -69.85K | -53.05K |
| CapEx % of Revenue | 0% | 0.02% | 0.01% | 0.01% |
| Acquisitions | - | - | - | - |
| Investments | - | - | - | - |
| Other Investing | 0 | 94.45K | 780K | 0 |
| Cash from Financing | -1.54M | 70.27M | 1.91M | 8.68M |
| Debt Issued (Net) | - | - | - | - |
| Equity Issued (Net) | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - |
| Other Financing | -2.04M | -1.71M | 1.72M | 98.64K |
| Net Change in Cash | - | - | - | - |
| Free Cash Flow | 1.42M | -621.58K | -1.84M | -8.32M |
| FCF Margin % | 0.34% | -0.1% | -0.36% | -1.53% |
| FCF Growth % | - | -1.44% | -1.95% | -3.53% |
| FCF per Share | 0.03 | -3.21 | -7.24 | -14.61 |
| FCF Conversion (FCF/Net Income) | -2688.56x | -1.15x | -13.76x | 15.74x |
| Interest Paid | 65.58K | 55.47K | 0 | 768.07K |
| Taxes Paid | 3.83K | 12.17K | 0 | 0 |
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | 1.37% | 0.37% | -59.53% |
| Return on Invested Capital (ROIC) | - | -1.11% | 0.09% | -37.71% |
| Gross Margin | 24.89% | 25.87% | 32.75% | 33.63% |
| Net Margin | -0.01% | 7.72% | 2.53% | -9.66% |
| Debt / Equity | - | 0.01x | 0.10x | - |
| Interest Coverage | 2.25x | -6.49x | 0.91x | -1.49x |
| FCF Conversion | -2688.56x | -1.15x | -13.76x | 15.74x |
| Revenue Growth | - | 44.34% | -13.59% | 5.78% |
| 2023 | 2024 | |
|---|---|---|
| THAILAND | 1.36M | 2.18M |
| THAILAND Growth | - | 60.31% |
| CAMBODIA | 621.62K | 601.53K |
| CAMBODIA Growth | - | -3.23% |
| CHINA | - | 8.37K |
| CHINA Growth | - | - |
| HONG KONG | - | 3.08K |
| HONG KONG Growth | - | - |
NewGenIvf Group Limited (NIVFW) reported $2.8M in revenue for fiscal year 2024. This represents a 32% decrease from $4.1M in 2021.
NewGenIvf Group Limited (NIVFW) grew revenue by 5.8% over the past year. This is steady growth.
NewGenIvf Group Limited (NIVFW) reported a net loss of $0.5M for fiscal year 2024.
NewGenIvf Group Limited (NIVFW) has a return on equity (ROE) of -59.5%. Negative ROE indicates the company is unprofitable.
NewGenIvf Group Limited (NIVFW) had negative free cash flow of $6.7M in fiscal year 2024, likely due to heavy capital investments.